Production (Stage)
Orchestra BioMed Holdings, Inc.
OBIO
$2.72
-$0.01-0.37%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -39.31% | -26.03% | -15.85% | -32.66% | -23.06% |
Total Depreciation and Amortization | 12.16% | 16.67% | 7.04% | 1.37% | 4.23% |
Total Amortization of Deferred Charges | -- | 933.33% | -- | -- | -- |
Total Other Non-Cash Items | 42.25% | 105.04% | -1.08% | 215.23% | 142.97% |
Change in Net Operating Assets | 46.02% | -1,075.00% | -204.24% | 401.80% | 58.47% |
Cash from Operations | -26.70% | -23.36% | -33.24% | 2.71% | 8.81% |
Capital Expenditure | -1,300.00% | -3,633.33% | -257.89% | -296.30% | 77.14% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 123.39% | -109.19% | -95.18% | 29.29% | 113.49% |
Cash from Investing | 121.79% | -111.32% | -95.70% | 28.41% | 113.46% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 405.56% | -66.67% | 375,775.00% | 98.84% | 63.64% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -1,744.44% | 230.39% | 375,775.00% | 98.84% | -99.97% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 45.92% | -129.13% | -29.11% | 117.02% | -564.37% |